Japan Life Insurance announced that it would spend $8.2 billion to acquire the life insurance company Resolution Life. On December 11th, Japan Life Insurance Mutual announced that it would spend about $8.2 billion to acquire the remaining 77% shares of the life insurance company Resolution Life. The transaction is expected to be completed in the second half of 2025. On the same day, Japan Life announced that it would acquire the remaining 20% shares of MLC Life Insurance from National Bank of Australia (NAB) and integrate MLC with Resolution Life.Spot gold fell in the short term, just breaking through the $2,690.00/oz mark, and the latest report was $2,689.72/oz, down 0.15% in the day.The New Zealand dollar fell to $0.57885, the lowest since October 2023.
Gold prices rose three times in a row, and brands such as Chow Tai Fook and Lao Fengxiang broke through 810 yuan. After a short-term shock, the gold trend became stronger. On December 11th, spot gold hit $2,700 per ounce, hitting a two-week high and rising for three consecutive days. As of press time, COMEX Gold reported $2,737.5 per ounce, up 0.7% in the day. In the domestic gold consumption market, the gold prices of gold brands such as Chow Tai Fook, Lao Fengxiang and Luk Fook Jewelry reached 812 yuan/gram, while the gold prices in Zhou Shengsheng reached 814 yuan/gram. (Dahe Finance Cube)Date of hearing the liquidation petition of R&F Property's subsidiary. On Wednesday, the Hong Kong court postponed the date of hearing the liquidation petition to December 16th, when representatives of R&F Properties (Hong Kong) will go to court with lawyers of Seatown Holdings Private Equity Fund. Seatown Holdings is supported by Singapore Temasek Holdings.Private placement: Positive factors in the stock market are accumulating. Recently, A-shares have fluctuated, and the latest strategies of many first-line private placements for investment at the end of the year and the beginning of the year have been released one after another. A number of private placements are optimistic about the market at the end of the year. Kou Zhiwei, a partner of chongyang investment, said that the "strengthening unconventional countercyclical adjustment" proposed by the policy at the end of the year inspired market confidence. At present, compared with the end of September, the market has a large increase, and the market has fully expected and priced the policy overweight. The further rise of the short-term market may need the support of strong economic recovery data. Judging from the recent overall investment trends of private placement, the reporter found that maintaining medium and high positions and maintaining high flexibility of portfolios have become the strategic focus of current private placement institutions. (CSI)
Sinotrans has set up a new company, including land international cargo transportation agency business. The enterprise search APP shows that recently, Sinotrans Logistics (Alashankou) Co., Ltd. was established with Chen Xin as its legal representative and registered capital of 10 million yuan. Its business scope includes: domestic container cargo transportation agency; International freight forwarder; Land international freight forwarding agent; Import and export agents, etc. Enterprise survey shows that the company is indirectly wholly-owned by Sinotrans.Net New Software won the bid for the public employment service platform project of Ankang Smart People's Society. According to the new news of Zhejiang University Network, recently, Net New Software, a new subsidiary of Zhejiang University Network, won the bid for the public employment service platform (customized software development) project of Ankang Smart People's Society. Ankang is the second batch of demonstration cities for improving the public employment service capacity, and the construction of the public employment service platform of Smart People Society is one of the key points for improving the public employment service capacity.Yongtai Bio-product, a new open-source shareholding company, was recognized by CDE for breakthrough therapy. On December 11th, official website, China National Medical Products Administration Drug Evaluation Center (CDE), recently announced that the anti-CD19 single-chain antibody chimeric antigen receptor T cell injection (CAR-T-19 cell injection for short) developed by Yongtai Bio-B (06978.HK) was successfully included in the list of breakthrough therapy varieties by CDE, and the indication was recurrence under 25 years old/.
Strategy guide 12-13
Strategy guide 12-13
Strategy guide 12-13
Strategy guide 12-13
Strategy guide 12-13